The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease

C. R. Brandt, P. Imesch, B. Spencer, B. Eliassi-Rad, N. A. Syed, S. Untawale, N. L. Robinson, Daniel Albert

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We have used a herpes simplex virus type 1 (HSV-1) ribonucleotide reductase (RR) null mutant (ICP6Δ) to determine if the HSV-1 RR is required for acute retinal disease. Injection of the ICP6Δ mutant into the vitreous induced mild transient signs of infection (vitreal infiltrate, retinal inflammation, and changes in retinal cytology). In contrast, the parental KOS and a revertant virus (ICP6Δ + 3.1) in which the RR gene had been restored, caused severe retinitis. Injection of media alone also induced mild transient signs of disease. Two months after infection, ICP6Δ injected eyes could not be distinguished from normal eyes. Repeated injection of ICP6Δ (3 times, 2 weeks apart) resulted in vitreal infiltrate near the site of injection but the retina did not appear damaged. The mutant, ICP6Δ, grew to peak titers 1 x 103 to 1 x 105-fold lower and cleared faster than KOS or ICP6Δ + 3.1 in the injected eyes suggesting that the reduced virulence was due to reduced ability of the virus to grow. These results show that the viral RR is required for acute retinal disease.

Original languageEnglish (US)
Pages (from-to)883-896
Number of pages14
JournalArchives of Virology
Volume142
Issue number5
DOIs
StatePublished - Jun 6 1997
Externally publishedYes

Fingerprint

Ribonucleotide Reductases
Retinal Diseases
Human Herpesvirus 1
Acute Disease
Injections
Viruses
Retinitis
Infection
Virulence
Cell Biology
Retina
Inflammation
Genes

ASJC Scopus subject areas

  • Genetics
  • Applied Microbiology and Biotechnology

Cite this

Brandt, C. R., Imesch, P., Spencer, B., Eliassi-Rad, B., Syed, N. A., Untawale, S., ... Albert, D. (1997). The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. Archives of Virology, 142(5), 883-896. https://doi.org/10.1007/s007050050126

The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. / Brandt, C. R.; Imesch, P.; Spencer, B.; Eliassi-Rad, B.; Syed, N. A.; Untawale, S.; Robinson, N. L.; Albert, Daniel.

In: Archives of Virology, Vol. 142, No. 5, 06.06.1997, p. 883-896.

Research output: Contribution to journalArticle

Brandt, CR, Imesch, P, Spencer, B, Eliassi-Rad, B, Syed, NA, Untawale, S, Robinson, NL & Albert, D 1997, 'The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease', Archives of Virology, vol. 142, no. 5, pp. 883-896. https://doi.org/10.1007/s007050050126
Brandt CR, Imesch P, Spencer B, Eliassi-Rad B, Syed NA, Untawale S et al. The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. Archives of Virology. 1997 Jun 6;142(5):883-896. https://doi.org/10.1007/s007050050126
Brandt, C. R. ; Imesch, P. ; Spencer, B. ; Eliassi-Rad, B. ; Syed, N. A. ; Untawale, S. ; Robinson, N. L. ; Albert, Daniel. / The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. In: Archives of Virology. 1997 ; Vol. 142, No. 5. pp. 883-896.
@article{54ed3e480a1c48f4b6251290a17056dc,
title = "The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease",
abstract = "We have used a herpes simplex virus type 1 (HSV-1) ribonucleotide reductase (RR) null mutant (ICP6Δ) to determine if the HSV-1 RR is required for acute retinal disease. Injection of the ICP6Δ mutant into the vitreous induced mild transient signs of infection (vitreal infiltrate, retinal inflammation, and changes in retinal cytology). In contrast, the parental KOS and a revertant virus (ICP6Δ + 3.1) in which the RR gene had been restored, caused severe retinitis. Injection of media alone also induced mild transient signs of disease. Two months after infection, ICP6Δ injected eyes could not be distinguished from normal eyes. Repeated injection of ICP6Δ (3 times, 2 weeks apart) resulted in vitreal infiltrate near the site of injection but the retina did not appear damaged. The mutant, ICP6Δ, grew to peak titers 1 x 103 to 1 x 105-fold lower and cleared faster than KOS or ICP6Δ + 3.1 in the injected eyes suggesting that the reduced virulence was due to reduced ability of the virus to grow. These results show that the viral RR is required for acute retinal disease.",
author = "Brandt, {C. R.} and P. Imesch and B. Spencer and B. Eliassi-Rad and Syed, {N. A.} and S. Untawale and Robinson, {N. L.} and Daniel Albert",
year = "1997",
month = "6",
day = "6",
doi = "10.1007/s007050050126",
language = "English (US)",
volume = "142",
pages = "883--896",
journal = "Archives of Virology",
issn = "0304-8608",
publisher = "Springer Wien",
number = "5",

}

TY - JOUR

T1 - The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease

AU - Brandt, C. R.

AU - Imesch, P.

AU - Spencer, B.

AU - Eliassi-Rad, B.

AU - Syed, N. A.

AU - Untawale, S.

AU - Robinson, N. L.

AU - Albert, Daniel

PY - 1997/6/6

Y1 - 1997/6/6

N2 - We have used a herpes simplex virus type 1 (HSV-1) ribonucleotide reductase (RR) null mutant (ICP6Δ) to determine if the HSV-1 RR is required for acute retinal disease. Injection of the ICP6Δ mutant into the vitreous induced mild transient signs of infection (vitreal infiltrate, retinal inflammation, and changes in retinal cytology). In contrast, the parental KOS and a revertant virus (ICP6Δ + 3.1) in which the RR gene had been restored, caused severe retinitis. Injection of media alone also induced mild transient signs of disease. Two months after infection, ICP6Δ injected eyes could not be distinguished from normal eyes. Repeated injection of ICP6Δ (3 times, 2 weeks apart) resulted in vitreal infiltrate near the site of injection but the retina did not appear damaged. The mutant, ICP6Δ, grew to peak titers 1 x 103 to 1 x 105-fold lower and cleared faster than KOS or ICP6Δ + 3.1 in the injected eyes suggesting that the reduced virulence was due to reduced ability of the virus to grow. These results show that the viral RR is required for acute retinal disease.

AB - We have used a herpes simplex virus type 1 (HSV-1) ribonucleotide reductase (RR) null mutant (ICP6Δ) to determine if the HSV-1 RR is required for acute retinal disease. Injection of the ICP6Δ mutant into the vitreous induced mild transient signs of infection (vitreal infiltrate, retinal inflammation, and changes in retinal cytology). In contrast, the parental KOS and a revertant virus (ICP6Δ + 3.1) in which the RR gene had been restored, caused severe retinitis. Injection of media alone also induced mild transient signs of disease. Two months after infection, ICP6Δ injected eyes could not be distinguished from normal eyes. Repeated injection of ICP6Δ (3 times, 2 weeks apart) resulted in vitreal infiltrate near the site of injection but the retina did not appear damaged. The mutant, ICP6Δ, grew to peak titers 1 x 103 to 1 x 105-fold lower and cleared faster than KOS or ICP6Δ + 3.1 in the injected eyes suggesting that the reduced virulence was due to reduced ability of the virus to grow. These results show that the viral RR is required for acute retinal disease.

UR - http://www.scopus.com/inward/record.url?scp=0031021047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031021047&partnerID=8YFLogxK

U2 - 10.1007/s007050050126

DO - 10.1007/s007050050126

M3 - Article

C2 - 9191855

AN - SCOPUS:0031021047

VL - 142

SP - 883

EP - 896

JO - Archives of Virology

JF - Archives of Virology

SN - 0304-8608

IS - 5

ER -